Understanding Price Growth in the Market for Targeted Oncology Therapies
The prices of targeted oncology therapies have grown substantially, but revenues have not. This is due in part to large declines in per-drug patient counts.
New Studies Highlight JAK Inhibitors’ Power as AD Treatment
Reducing Polycythemia Vera–Associated Thrombotic Risk Through Iron Regulation
Financial, Housing, Food Insecurity Raises Risk of Hospital, ED Visits
ANTHEM-UC: Icotrokinra (JNJ-2113) Shows Promise for Ulcerative Colitis